Effect of intestinal flora characteristics on the therapeutic effect of different chemotherapy regimens for colorectal cancer

doi:10.3877/cma.j.issn.2095-2015.2024.01.009

Abstract

Abstract:

Objective

To explore the influence of intestinal flora characteristics on the therapeutic effect of different chemotherapy regimens for colorectal cancer.

Methods

A prospective case-control analysis was conducted to select 248 patients with stage Ⅳ colon cancer admitted to the Second Hospital of Huangshi City from June 2019 to November 2020. Among them, 130 patients treated with capecitabine+oxaliplatin (XELOX) chemotherapy regimen were randomly divided into two groups: XELOX combination group (XELOX+bifidobacterium lactobacillus triple live bacterial tablets) and XELOX group; 118 patients treated with oxaliplatin+calcium nitrite+5-fluorouracil (FOLFOX) chemotherapy regimen were randomly divided into two groups: the FOLFOX combination group (FOLFOX+ bifidobacterium lactobacillus triple live bacterial tablets) and the FOLFOX group. The gut microbiota in fecal samples before and after treatment in each group were detected, and the clinical treatment effects of each group were compared.

Results

Compared with the XELOX group, bifidobacteria, lactobacilli and bacteroides in the XELOX combination group increased significantly after treatment, while enterobacteria, enterococcus and fusobacterium decreased significantly (P<0.05); Compared with the FOLFOX group, bifidobacteria, lactobacilli and bacteroides in the FOLFOX combination group were significantly increased after treatment, while enterobacteria, enterococcus and fusobacterium were significantly reduced after treatment (P<0.05). The total effective rate of the XELOX combination group was significantly higher than that of the XELOX group (56.92% vs. 43.08%, P<0.05), and the mortality rate during the 12 month follow-up period was significantly lower than that of the XELOX group (21.54% vs. 49.23%, P<0.05); The total effective rate of the FOLFOX combination group was significantly better than that of the FOLFOX group (52.54% vs. 44.07%, P<0.05), and the mortality rate during the 12 month follow-up period was significantly lower than that of the FOLFOX group (22.03% vs. 57.63%, P<0.05).

Conclusion

There is a significant imbalance of intestinal flora in patients with advanced colon cancer. Drug intervention to regulate intestinal flora can improve the treatment effect and improve the survival of patients.

Key words: Colon cancer, Intestinal flora, Chemotherapy, Clinical effect, Prognosis

Hong Xie, Na Li, Shangri Li, Tao Xie. Effect of intestinal flora characteristics on the therapeutic effect of different chemotherapy regimens for colorectal cancer[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(01): 53-56.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.01.009

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I01/53

Figures/Tables 2

References 17

[1]	Teufel A, Li M, Gerken M, et al. Second Cancer After Additive Chemotherapy in Patients With Colon Cancer[J]. Clin Colorectal Cancer, 2022, 21(4): 354-361.
[2]	Rios-Valencia J, Cruz-Reyes C, Galindo-García TA, et al. Mismatch repair system in colorectal cancer. Frequency, cancer phenotype, and follow-up[J]. Rev Gastroenterol Mex(Engl Ed), 2022, 87(4): 432-438.
[3]	Torregrosa C, Pernot S, Vaflard P, et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer(BEFLICO): An AGEO multicenter study[J]. Int J Cancer, 2022, 151(11): 1978-1988.
[4]	韩震, 王靖, 李卉, 等. 双歧杆菌联合辅助化疗对结直肠癌患者肠道菌群及免疫功能的影响[J]. 中国医学创新, 2022, 19(1): 29-33.
[5]	Ichikawa N, Homma S, Funakoshi T, et al. The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study[J]. Surg Today, 2022, 52(8): 1134-1142.
[6]	Al Sabbagh C, Agapova E, Boudy V, et al. Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin(FOLFOX) mixture[J]. J Oncol Pharm Pract, 2022, 28(6): 1303-1314.
[7]	Cavalleri T, Greco L, Rubbino F, et al. Tumor-associated macrophages and risk of recurrence in stage III colorectal cancer[J]. J Pathol Clin Res, 2022, 8(4): 307-312.
[8]	Fernández Montes A, Élez E, Vivancos A, et al. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer[J]. Clin Transl Oncol, 2022, 24(6): 1209-1214.
[9]	张艺璇, 周秀彦, 高湘曼. 益生菌干预对结肠癌患者术后化疗并发症,预后及肠道菌群的影响[J]. 现代消化及介入诊疗, 2020, 25(6): 768-771.
[10]	Zhang J, Chen Y, Sun Y, et al. Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine[J]. Drug Delivery, 2018, 25(1): 1175-1181.
[11]	Guo J, Huang L. Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy[J]. Nat Protoc, 2022, 17(8): 1818-1831.
[12]	Sun L, Zhang X, Gong P, et al. Clinical Efficacy of Bevacizumab Plus XELOX Chemotherapy in Colorectal Cancer and Application Value of Mindfulness-Based Stress Reduction Intervention[J]. Altern Ther Health Med, 2022, 28(6): 65-71.
[13]	杨祎, 王娜, 贾菲, 等. 益髓健脾汤联合XELOX方案治疗结肠癌术后患者对肠道菌群及预后影响分析[J]. 世界中西医结合杂志, 2023, 18(2): 392-395.
[14]	Wang F, He MM, Xiao J, et al. Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer(VITALITY Study)[J]. Clin Cancer Res, 2022, 28(19): 4232-4239.
[15]	Zhou M, Thompson TD, Lin HY, et al. Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients[J]. Clin Colorectal Cancer, 2022, 21(2): e62-e75.
[16]	杨祎, 何颖华, 贾菲, 等. 双歧杆菌三联活菌胶囊联合FOLFOX方案用于结直肠癌术后对肠道微生态及抗肿瘤免疫应答的影响[J]. 湖南师范大学学报(医学版), 2022, 19(1): 95-98.
[17]	陈启仪, 田宏亮, 杨波, 等. 不同肠道准备方式对菌群移植疗效及安全性的影响[J]. 中华胃肠外科杂志, 2020, 23(Z1): 48-55.

时间	组别	例数	双歧杆菌	乳酸杆菌	肠杆菌	肠球菌	类杆菌	梭杆菌
治疗前	XELOX联合组	65	7.09±0.78	6.49±0.72	9.31±0.82	8.05±1.43	7.19±0.75	9.91±0.54
	XELOX组	65	7.16±0.63	6.68±0.85	9.48±0.74	8.12±1.65	7.29±0.52	9.86±0.77
	FOLFOX联合组	59	7.05±0.81	6.62±0.63	9.33±1.02	8.22±1.31	7.21±0.71	9.89±0.52
	FOLFOX组	59	7.03±0.75	6.67±0.75	9.41±0.84	8.03±1.62	7.09±0.88	9.68±0.65
F			0.482	0.187	0.337	0.692	0.731	0.381
P			0.318	0.429	0.581	0.264	0.172	0.601
治疗后	XELOX联合组	65	8.19±0.61^ab	8.11±0.81^ab	8.47±1.28^ab	7.28±0.94^ab	8.81±0.73^ab	8.22±0.09^ab
	XELOX组	65	7.09±0.95	6.68±0.91	9.31±1.01	8.32±1.62	7.01±0.85	9.91±0.70
	FOLFOX联合组	59	8.11±0.72^ac	8.07±0.73^ac	8.37±1.31^ac	7.39±1.06^ac	8.89±0.65^ac	8.27±1.06^ac
	FOLFOX组	59	7.05±0.84	6.72±0.83	9.40±0.89	8.24±1.55	7.11±0.82	9.82±0.65
F			3.281	3.932	2.819	4.810	4.012	3.109
P			0.018	0.016	0.029	0.003	0.007	0.013

时间	组别	例数	双歧杆菌	乳酸杆菌	肠杆菌	肠球菌	类杆菌	梭杆菌
治疗前	XELOX联合组	65	7.09±0.78	6.49±0.72	9.31±0.82	8.05±1.43	7.19±0.75	9.91±0.54
	XELOX组	65	7.16±0.63	6.68±0.85	9.48±0.74	8.12±1.65	7.29±0.52	9.86±0.77
	FOLFOX联合组	59	7.05±0.81	6.62±0.63	9.33±1.02	8.22±1.31	7.21±0.71	9.89±0.52
	FOLFOX组	59	7.03±0.75	6.67±0.75	9.41±0.84	8.03±1.62	7.09±0.88	9.68±0.65
F			0.482	0.187	0.337	0.692	0.731	0.381
P			0.318	0.429	0.581	0.264	0.172	0.601
治疗后	XELOX联合组	65	8.19±0.61^ab	8.11±0.81^ab	8.47±1.28^ab	7.28±0.94^ab	8.81±0.73^ab	8.22±0.09^ab
	XELOX组	65	7.09±0.95	6.68±0.91	9.31±1.01	8.32±1.62	7.01±0.85	9.91±0.70
	FOLFOX联合组	59	8.11±0.72^ac	8.07±0.73^ac	8.37±1.31^ac	7.39±1.06^ac	8.89±0.65^ac	8.27±1.06^ac
	FOLFOX组	59	7.05±0.84	6.72±0.83	9.40±0.89	8.24±1.55	7.11±0.82	9.82±0.65
F			3.281	3.932	2.819	4.810	4.012	3.109
P			0.018	0.016	0.029	0.003	0.007	0.013

组别	例数	CR	PR	SD	PD	总有效率	死亡率
XELOX联合组	65	9(13.85)	28(43.08)	22(33.85)	6(9.23)	37(56.92)^a	14(21.54)^a
XELOX组	65	5(7.69)	21(32.31)	28(43.08)	9(13.85)	28(43.08)	32(49.23)
FOLFOX联合组	59	8(13.56)	23(38.98)	21(35.59)	7(11.86)	31(52.54)^b	13(22.03)^b
FOLFOX组	59	4(6.78)	22(37.29)	23(38.98)	10(16.95)	26(44.07)	34(57.63)
χ²						21.572	34.071
P						0.001	0.001

组别	例数	CR	PR	SD	PD	总有效率	死亡率
XELOX联合组	65	9(13.85)	28(43.08)	22(33.85)	6(9.23)	37(56.92)^a	14(21.54)^a
XELOX组	65	5(7.69)	21(32.31)	28(43.08)	9(13.85)	28(43.08)	32(49.23)
FOLFOX联合组	59	8(13.56)	23(38.98)	21(35.59)	7(11.86)	31(52.54)^b	13(22.03)^b
FOLFOX组	59	4(6.78)	22(37.29)	23(38.98)	10(16.95)	26(44.07)	34(57.63)
χ²						21.572	34.071
P						0.001	0.001

Please choose a citation manager

Content to export